COMMUNIQUÉS West-GlobeNewswire

Flaggemelding
22/08/2025
Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag solgt 2 000 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS ingen aksjer i PCI Biotech Holding ASA.
Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
22/08/2025
PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in [...]
BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer
22/08/2025
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer [...]
Repligen Corporation to Present at Upcoming September Conferences
22/08/2025
WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending three upcoming [...]
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
22/08/2025
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems [...]
Trading by management and close relations of management
22/08/2025
Please read the announcement in PDF Attachment 2025_39_Trading_By_Management
Flaggemelding
22/08/2025
Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag kjøpt 240 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS 2 000 000 aksjer, noe som utgjør 5,36% av aksjene i PCI [...]
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
22/08/2025
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL’s primary listing on the ASX will remain unchanged as a [...]

Pages